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A systematic literature review was conducted to establish whether gender specific treatment 
exists for patients with Chronic Obstructive Pulmonary Disease (COPD), specifically, women 
with (COPD). The PICO question developed for this review is as follows: In women with 
confirmed diagnoses of COPD, does gender-specific treatment, compared to standard treatment, 
impact the frequency of exacerbations? Could the number of COPD exacerbations in women be 
reduced by incorporating interventions designed with (female) gender in mind? Four databases 
were included in the search: CINAHL, Pubmed, Medline, and Nursing and Allied Health. 
Articles included addressed gender differences in relation to the disease process, medication(s), 
or overall treatment. There were 16 articles selected for this review. This analysis found gender 
differences with regards to lung development, disease presentation, diagnosis, exacerbations, and 
prognosis. A definitive answer to the PICO question was not found from this systematic review, 
yet future research is warranted to determine whether gender differences to exist with regards to 
treatments/interventions in patients with COPD. Recommendations for practice, research, 
education, and policy are based on articles included within the review. 
Keywords: Chronic obstructive pulmonary disease, COPD, women or female, gender 





Reducing Disease Exacerbation in Women with Confirmed COPD:  A Systematic 
Literature Review 
      Chronic obstructive pulmonary disease (COPD) is the third most common cause of death 
in the United States (US) (Guarascio et al., 2013). In 2010, the cost of COPD in the US was 
projected to be approximately $50 billion, which includes $20 billion in indirect costs and $30 
billion in direct health care expenditures (Guarascio et al., 2013). COPD is a progressive disease 
and the cost of treating this illness is not decreasing in the US, however, earlier diagnosis and 
medication advancements can add years to patient lives (Guarascio et al., 2013). COPD was 
previously considered a male dominant disease process, but current data reveals women with 
COPD now exceed men in hospitalization and death (Celli et al., 2010). Celli et al. (2010) 
designed a study a three-year study, -Toward a Revolution COPD (TORCH), to evaluate sex 
differences related to risk of death from COPD, TORCH results indicate women were 16 percent 
less likely to die from the disease, but when covariates such as body mass and airflow 
obstruction were corrected, the results between genders were equal. Data indicates that with each 
progressive stage of COPD, as defined in the GOLD guideline, the cost to treat patients increases 
(Guarascio et al., 2013). Patients with stage I COPD experienced the lowest direct cost of $1681 
per patient per year, stage II patients will incur $5037 per patient per year, and those in stage III 
had the highest cost of care, $10,812 per patient per year (Guarascio et al., 2013).  
COPD varies in etiology. It is a progressive disease of airway obstruction caused by 
inflammation; which narrows airways, increases mucus production, and subsequently creates a 
cough; all of which can create dyspnea for the individual (Breyer et al., 2011).  Primary risk 
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factors for COPD include cigarette smoking and biomass.  The disease process included 
pulmonary and non-pulmonary manifestations, with dyspnea and cough as the most prevalent 
symptoms in patients with COPD (Breyer et al., 2011). After a diagnosis of COPD, a referral for 
pulmonary function testing to establish baseline spirometry values is a prudent next step (Breyer 
et al., 2011).  
Early diagnosis is key in controlling and limiting progression of COPD; once thought to 
be impossible (Criner et al., 2019). Smoking cessation, vaccinations, supplemental oxygen for 
hypoxemic patients, and lung volume reduction surgery in selected patients all improve survival; 
smoking cessation also attenuates disease progression (Criner et al., 2019). Patients with COPD 
experience episodes of increased symptomology that may necessitate hospitalization and intense 
management of the illness at times (Criner et al., 2019). Secondary infections have their own 
symptoms and may worsen existing disease (Criner et al., 2019), further increasing risk for an 
exacerbation and need for hospitalization.   
Emerging research suggests that women and men may progress differently through the 
disease process (Celli et al., 2011; Criner et al., 2019). Research up until this point has primarily 
focused on male with COPD (Grabicki et al., 2019) It is now recognized that COPD in women is 
a major healthcare problem worldwide (Cote & Chapman, 2009). This may be due to increasing 
rates of cigarette smoking in women, hazardous work environments, and/or wood smoke 
exposure. Women’s airways are also smaller than men’s and it is possible women require less of 
a caustic agent to damage their lungs or that the exposure to caustic agents is higher due to their 
smaller airways (Martinez et al., 2012). The burden of COPD among women continues to grow; 




      The following PICO question was developed to guide the systematic review of the 
literature: In women with confirmed diagnoses of COPD (P) does gender-specific treatment (I) 
compared to standard treatment (C) impact the frequency of exacerbations (O)? The research 
question included a comparison group, as it was hypothesized that specific treatment by gender 
may offer better health-related quality of life (HRQoL) and disease management in women 
affected by COPD in addition to lessening the frequency and number of exacerbations. 
Clinical Significance for Advanced Practice 
      Advanced practice providers (APP) readily see female patients with COPD in the primary 
care clinic setting. Recommending the best possible medication or treatment regimen for this 
subpopulation allows the opportunity to educate and facilitate a COPD care plan that will not 
only promote better HRQoL, but also fewer COPD exacerbations. 
Methods 
      A systematic literature review was done to produce current articles regarding the PICO 
question cited above. Electronic databases were utilized to find relevant materials related to 
treatment of women with COPD, to evaluate whether gender-specific or standard treatment 
affected reduced symptoms of disease, and if those treatments decrease the number of 
exacerbations women experience. The primary focus of this review is whether or not there is a 
difference when gender is considered in the treatment of COPD.  
Database 
      The databases searched for this review were the Cumulative Index of Nursing and Allied 
Health (CINAHL), PubMed, Medline, and Nursing and Allied Health. Restrictions added to the 
search were that articles had to be full text, printed in the English language, and peer reviewed. 
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The articles had to be published between the years 2010 and 2020 assuring currency of research. 
The initial search results can be viewed in the Appendix, Table 1. 
Abstraction Process 
The abstraction process limited the key words to Chronic Obstructive Pulmonary 
Disease, COPD, women, treatment, exacerbations, gender differences, interventions, outcomes, 
and female. The initial search yielded 9071 articles (see Table 1 in the Appendix). Article criteria 
was further reduced based on the following words; Chronic Obstructive Pulmonary Disease, 
women or female, gender differences, and exacerbations. This brought the article total to 38. 
Results can be viewed in the Appendix, Table 2. 
Search Strategies 
      Thirty-eight articles were reviewed based on the abstract and content to decide if they fit 
the purpose of the literature review. They were excluded if they did not address the central 
themes related to gender comparison or female treatment related to COPD exacerbations. If a 
gender difference was noted in the article with regards to lung development, risk factors, testing, 
diagnosis, or treatment, the article was included in the analysis. Exclusion versus inclusions 
criteria and findings can be viewed in can be viewed in the Appendix, Table 3. 
Literature Review Process 
      There were 16 articles included in this literature review. Research on COPD in females is 
relatively new. Previous research has foculsed on the male population. Similarities among the 
articles in the review suggest that differences do exist between genders with relation to COPD 
(Augusti et al., 2010; Breyer et al., 2011; Celli et al., 2011; Kohler et al., 2013, Martinez et al., 
2012). Only one article clearly addressed the clinical question regarding gender and treatment 
and its effect on disease exacerbation (Celli et al., 2011). No research was found to support the 
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use of specific medication protocols or treatment plans for females with COPD (Celli et al., 
2011) Several articles offer partial answers to the question and will help steer future research. 
Further data related to these articles can be found in the Appendix, Table 4.   
Study Characteristics 
      Of the 16 studies researched, two were level I studies, one study was a level II study, 
twelve were level III studies, and one was a level IV study (see Table 4 in the Appendix). The 
level I studies consisted of two systematic reviews. The level II study looked at laboratory data 
for comparison. The level III studies consisted of trials, measurement comparison, trend 
comparison, straight-forward comparison, data review, cross-sectional study, randomized control 
study, and multiple regression analysis. The single level IV study utilized a multi-variate logistic 
regression model to identify proteins of interest (Kohler et al., 2012). The population samples 
included both men and women with COPD. All studies had more male participants than female 
participants. One study used veterans who had developed COPD and hospital admissions rates to 
assess for gender differences (Fuhrman et al., 2011).  Only one of the studies, (Wedzicha et al., 
2019) specifically addressed, medications as an intervention/treatment, and its effect related to 
gender.  Wedzicha et al. (2019) did not find the results differed between genders with regard to 
medication used to treat COPD.  The medication classes in this study were a combination inhaled 
long acting bronchodilator and corticosteroid. 
Definitions: 
Six-minute walk: The distance that is walked in a 6-minute period. There are predicted normal 
values for the six minute-walk based on age and sex. This screening test is predictive of 
functional status (Torres et al., 2011). 
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Biomass:  Fumes related to household work, occupationally related, or woodsmoke (Cote & 
Chapman 2009). 
Bronchoalveolar lavage cell proteome: A proteome obtained during a bronchoalveolar lavage 
(BAL). BAL is a lung fluid sample obtained via normal saline inserted into the lung and drawn 
out carrying lung fluid with it (Kohler et. al., 2013) 
BODE index: An index that considers several criteria to estimate a survival rate in years. The 
criteria are FEV1 % of predicted, six-minute walk distance, mMRC dyspnea scale, and BMI 
(Cote & Chapman, 2009). 
DOSE index: (D) dyspnea, (O) airflow obstruction, (S) current smoking status, (E) frequency of 
exacerbations in the past year (Wang et al., 2017). 
FEV1: The amount of air a patient can expel from his/her lungs in one second. This maneuver is 
done during spirometry testing, also referred to as pulmonary function testing. This test produces 
a predicted value for a gender and age. The test assesses lung function based on what percent a 
patient scores in relation to the predicted lung function for age and gender. Lung function in 
those with COPD, elicits reduced scores, in relation to predicted FEV1 %. The guideline for a 
positive diagnosis of COPD is achieving a score of 80% (or less) of predicted.  80% of the 
predicted lung function would suggest mild disease; 50% to 79% suggests moderate disease, 30-
49% suggests severe disease, and less than 30% is considered very severe or end stage disease 
(Cote & Chapman, 2009). 
Lung Information Needs Questionnaire (LINQ).  This iinstrument can be used as a baseline for 
establishing information needs/patient understanding of COPD and its treatment for comparison 
with future evaluations (Wakabayashi et al., 2019). 
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mMRC: Modified Medical Research Council Dyspnea scale is used to distinguish severity of 
dyspnea in respiratory illness (Cote & Chapman, 2009). 
SGRQ:  St. George’s Respiratory Questionnaire is utilized in those with obstructive lung 
diseases. It measures disease impact on the patient’s overall health, daily activities, and 
perceived well-being (Celli et al., 2011). 
TORCH: Toward a Revolution in COPD Health. This was a 3-year study to determine sex 




      There are differences between men and women at a cellular level. Kohler et al. (2012) 
studied the gender differences of bronchoalveolar lavage cell proteome in COPD patients. 
Kohler et al. (2012) found there are changes that occur in female COPD patient’s proteomes that 
do not occur in male patients proteomes. It was learned that these changes also do not happen in 
female non-smokers (Kohler et al., 2012). Kohler et al. (2012) demonstrated that there is a 
specific change in female smokers who develop COPD. The differences identified in these 
studies further support that gender differences exist in COPD phenotypes and diagnosis and 
treatment on the basis of gender warranting further investigation. 
      De Torres, et al. (2011) did a pilot study looking at biomarker levels in a cohort of COPD 
patients.  Of these patients 80 were smokers without COPD (40 male and 40 female) and 152 
were stable COPD patients (76 male and 76 female), with similar airflow obstruction at time of 
study. De Torres, et al. (2011) found there was statistical difference in level IL-6, IL16, and 
VEGF levels between women and men with COPD (de Torres et al., 2011). The researchers 
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acknowledge that this study needs to be replicated to further support or refute these preliminary 
findings. 
      Breyer et al. (2011) studied the role of leptin in relation to gender differences in COPD. 
They found women with COPD had an increase in leptin compared to men with COPD and 
healthy females without COPD. Leptin secretion increased with increasing fat mass to a greater 
extent in COPD women when compared with their male counterparts, supporting the hypothesis 
of gender-specific leptin metabolism in COPD (Breyer et al., 2011). It is unknown at this time if 
increased weight carries an increased risk of symptoms in COPD patients. What is known is 
significant: There is a change in leptin metabolism in women with COPD. 
Factors Impacting Gender Response to COPD 
      Potential variable related to sex differences in tobacco susceptibility causing COPD 
include differences in metabolism, hormonal influences, lung anatomy, inhalation technique, or a 
dose exposure because women’s lungs are smaller than men’s (Criner et al. 2019). Wood smoke 
exposure is possible in homes that utilize wood as a heat source. It is known that cigarette 
smoking is the leading contributor of COPD causes (Criner et al., 2019). Airway hyper-
responsiveness in men is associated with allergies and asthma, whereas airway hyper-
responsiveness in women it is associated with smoking indicating that airways react differently 
in men and women (Criner et al., 2019). It is known that women with COPD are frequently 
initially misdiagnosed with asthma and not tested with spirometry until after their first 
hospitalization. Bade et al. (2019) suggest that prior to a hospitalization, women were less likely 
to have pulmonary function testing or be treated with antimuscarinic or combined long-acting 
bronchodilator/inhaled corticosteroid inhalers. This demonstrates the delay that happens in the 
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diagnosis of COPD and treatment in women. It is now recognized that early diagnosis is proven 
to slow disease progression (Bade et al., 2019).  
Readmission is strongly influenced by comorbidities, suggesting that individualized and 
comprehensive case management may reduce readmission risk for women and men. (Bade et al., 
2019) Cote et al. (2009) considered the unique findings of two separate COPD related studies 
conducted by Miravitlles et al. (2006) and Chapman et al. (2001). These two studies, essentially 
equal on all accounts, were developed into cases for providers to review for purposes of making 
a COPD diagnosis. Women with COPD were diagnosed 11-16% less correctly than men with 
COPD by the participating providers. However, when spirometry was utilized in the given cases, 
the primary care providers (PCPs) were less likely to miss a diagnosis of COPD in both men and 
women. 
Gender Effects of Medications Approved for COPD Treatment 
      A study by Wedzicha et al. (2019) reviewed the combination medication 
indacaterol/glycopyronium, which is a long-acting beta agonist (LABA) and an inhaled 
corticosteroid, and whether gender differences were found when taking this medication 
regularly. Although there were gender differences in baseline characteristics between men and 
women with COPD in the Wedzicha et al. (2019) study, indacaterol/glycopyronium 
demonstrated similar trends for exacerbation, prevention, and lung function improvement in men 
and women with moderate-to-very severe COPD. In addition to the above, Wedzicha et al. 
(2019), compared indacaterol/glycopyronium against the drug combination 
salmeterol/fluticasone, which is also a LABA/corticosteroid combination medication. Both of 
these medications are administered via a multi-dose inhaler. The indacaterol/glycopyronium dose 
was 110/50 ug once daily and the salmeterol/fluticasone dose was 50/500 twice daily. Although, 
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the prior medication combination would be more convenient, it didn’t offer an advantage of 
improving COPD outcomes in women. (Wedzicha et al., 2019)  
Barriers to Care/Education 
Significant gender-related differences in the perception of COPD healthcare delivery 
exist, revealing an opportunity to better understand what influences attitudes and to improve care 
for both men and women with COPD (Martinez et al., 2012). Martinez et al. (2012) showed that 
women generally made less money, were diagnosed later, and felt they had a harder time 
reaching a provider to discuss COPD care needs. Based on questionnaire results, it appears that 
there is a gap in education for female patients (Martinez el al., 2012). This occurred even though 
the availability of physicians, rehabilitation services, and insurance were similar to that of men. 
Wakabayashi et al. (2019) explored gender differenced in COPD knowledge utilizing the LINQ. 
They found that females displayed significantly higher information needs than men. No 
difference was seen between sexes on subjects of knowledge, medicine, smoking, and exercise 
domains; the gender difference involved knowledge about avoidance of disease exacerbation. 
Disease State and Dyspnea Disconnect 
The main theme throughout the articles in this review is that female patients report 
greater dyspnea than is expected for measured lung function. The Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) was a large multi-country, 
multi-patient study conducted in 46 centers. This study was designed to define COPD 
phenotypes and identify biomarkers to aid in the prediction of disease progression (Augusti, et 
al., 2010). The severity of airflow limitation in COPD patients was poorly related to exacerbation 
reported in the year prior to the study (Augusti et al., 2010). Celli et al. (2011) found that even 
when correcting for degree of airflow obstruction, women report more anxiety and depression, 
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worse symptoms, lower exercise capacity, more airway hyperresponsiveness, and worse HRQoL 
than men. This could be related to smaller airways and disease progression.  Much less is known 
about any sex differences in mortality and the factors that may affect it in the patients with 
COPD (Celli et al., 2011). 
Exacerbations and Hospitalizations Related to Exacerbations 
      Acute exacerbation of COPD (AE-COPD) are major events in the disease course, 
especially when the necessitate a hospitalization (Fuhrman et al., 2011). Grabicki et al. (2019) 
found that women had significantly more exacerbations than men. In fact, they observed that 
women experienced at least two to four more exacerbations in a two year interval compared to 
men who experienced exacerbations in the same time interval. Overall women have fewer 
comorbidities as a whole (Bade et al., 2019). Comorbidities can exacerbate COPD symptoms and 
in some cases cause a need for hospitalization. There is a correlation for both men and women 
regarding exacerbations, but it is slightly stronger for woman (Fuhrman et al., 2011). Fuhrman et 
al. (2011) found in a French study that COPD exacerbations were increasing for women and 
follow illness trends such as influenza.   
Prognosis of COPD 
      Prognosis is typically based on how well the treatment works for the patient, whether or 
not the patient quits smoking, and how effectively they are with self-management (Wang et al., 
2017). The DOSE index is a good predictor of patient prognosis (Wang et al., 2017).  Wang et al. 
(2017) conducted an exploratory study that demonstrated higher physical activity, higher BMI, 
and female sex were important factor for lowering the DOSE index, thereby offering ways that 
might improve the prognosis of patients with COPD. 
Gaps in Literature 
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      The primary gap with regards to gender-based COPD treatment currently is trialing 
medications head-to-head with specific care plans that are developed by patient gender.  This is 
an area where further research is needed in order to impact the frequency and severity of COPD 
exacerbations and outcomes for women.   
Discussion 
This systematic literature review focuses on whether gender-specific versus standard 
treatment could reduce exacerbations in women with COPD. Over a five-year study period 
Grabicki et al. (2019) attempted to evaluate whether significant differences could be found 
between Polish women and men suffering from COPD, with regard to clinical presentation, 
pulmonary function test results, comorbidities, and prognosis. Grabicki et al. (2019) found 
gender differences existed for exacerbations, comorbidities and prognosis. Women had more 
exacerbations, less comorbidities on average (although a wider distribution of comorbidities), 
and worse prognosis with less cigarette exposure than their male counterparts (Criner et al., 
2019). Agusti et al. (2010) found that when subjects of similar age, and gender were analyzed by 
BODE scores, females reported less smoking exposure and more exacerbations than their male 
counterparts. In stable COPD patients with similar airflow obstruction, there are gender 
differences in plasma biomarker levels and in the association between biomarker levels and 
important clinical or physiological variables (de Torres et al., 2011). de Torres et al. (2011) 
acknowledges that further research is needed beyond their pilot study to further validate their 
findings. de Torres et al. (2011) suggest their study can serve as a hypothesis for future research. 
Interestingly, in the de Torres et al. (2011) study, there was no difference in the plasma 
biomarker levels in smokers without COPD. 
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      Women achieve peak lung function earlier than males (15 years versus 22 years) (Criner 
et al., 2019). This is of significance because women are more likely to develop COPD with less 
tobacco exposure than men, thus suggesting a developmental component difference in this 
disease (Criner et al., 2019). Potential causes of sex differences in tobacco susceptibility include 
differences in metabolism, hormonal influences, lung anatomy, inhalation technique, or a dose 
exposure because women’s lungs are smaller than men’s (Criner et al., 2019). Airway 
hyperactivity in men is associated with allergies and asthma, whereas in women it is associated 
with smoking; indicating airways react differently in men and women (Cote & Chapman, 2009). 
Women tend to report a lesser pack-year history than men diagnosed with COPD (Criner et al., 
2019). While studies are varied on the subject of smoking, newer literature suggest women are 
more susceptible to the harmful effects of smoking (Criner et al., 2019), possibly due to 
anatomical structure.  Women’s smaller airways may expose them to a larger quantity the 
chemicals in cigarette smoke (Cote & Chapman 2009; Criner et al., 2019). 
      Women tend to be under-diagnosed with COPD (Ford et al., 2014). Use of spirometry 
testing reduces under-diagnosing and in many instances PCPs just fail to test (Cote & Chapman, 
2009). It is harder to overlook an abnormal test result, especially when they align with a COPD 
diagnosis. 
      Currently there is limited research on gender-based treatment. Wedzicha et al. (2019) 
post-hoc analysis in the FLAME study, found IND/GLY did not out-perform SFC for 
exacerbation prevention in women with COPD, despite gender differences in baseline 
characteristics in lung function. Women reported greater improvement in quality of life with 
IND/GLY (Wedzicha et al., 2019), yet this assertion was not supported by decreased 
exacerbations or disease progression (Wedzicha et al., 2019). However, (Wedzicha et al., 2019) 
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found IND/GLY didn’t worsen the disease. There appears to be a disconnect as women do not 
report the same symptom relief or increase in (HRQoL). This does not mean that men and 
women should be treated the same or different. There just isn’t enough information to make this 
determination with what we currently know about this disease and its impact on female gender. 
Medication regimens are tailored based on disease characteristics and patient symptomology. 
Non-pharmacologic therapies such as pulmonary rehabilitation should be available to all patients 
with COPD. It has been shown that the efficacy of both oxygen therapy and exercise therapy 
may vary according to gender (Cote & Chapman 2009). 
      Women report more dyspnea and less frequency of cough and phlegm than men with 
same disease state (August et al., 2010). Common comorbidities experienced concurrently with 
COPD by women include heart disease, diabetes, stroke, anxiety, depression, obesity, 
osteoporosis, and arthritis (Augusti et al., 2010). While Augusti et al. (2010) could list 
differences in comorbidities it is unknown what causes the differences COPD symptoms in 
relation to them. It could encompass female anatomy, comorbidities, and/or possibly treatment 
effects. Breyer et al. (2011) discusses a study done by Ahonen et al. (2008) that demonstrated 
decreased plasma concentrations of the anti-inflammatory adiponectin in women and increased 
CRP in men that may contribute to symptom differences in the etiology of COPD between 
genders. This is why it is so important to further evaluate women and the various etiologies and 
effects of COPD has on their health and HRQoL. 
      When compared to men, women frequently use an emotion-focused coping strategy, a 
response characterized by such emotions as anxiety and depression (Martinez et al., 2012).  
Anxiety and depression may be contributing to the feeling dyspnea witnessed at increased rate in 
women in relation to the disease process. Martinez et al. (2012) found that as sources of disease 
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education for patients with COPD expand, women are now obtaining information about their 
disease from online support groups, and fewer women are obtaining disease information from 
their physician as compared to how men gain insights into and understanding COPD. This 
related to the women feeling that the diagnosis was initially delayed and that contact with their 
provider was difficult. This fact in itself creates potential for anxiety in a patient male or female. 
      When women are compared to men with the same state of disease and comorbidities, the 
BODE is a good indicator of mortality (Wang et al., 2017) The BODE index considers patient’s 
body mass index, airflow obstruction (from spirometry testing), dyspnea, and exercise capacity 
(Wang et al., 2017). Wang et al. (2017) asserts, the DOSE index may be a better indicator for 
overall prognosis of COPD. 
      COPD is a chronic illness that is partially self-managed (Wakabayashi et al., 2019). For a 
patient to successfully manage COPD in the home setting and avoid the need for medical 
intervention (up to and including hospitalization), education is key (Wakabayashi et al., 2019). 
Patients need to have knowledge about disease management, who to contact during an 
exacerbation or crisis, and medical coverage. Despite reporting similar access to healthcare 
insurance, physicians, and pulmonary rehabilitation, more women than men reported insurance 
as a barrier to at least one aspect of their care (Martinez et al., 2012). Patients with early stage to 
mild COPD are not perceived as high risk and subsequently might not receive adequate self-
management education, and this may explain why the total LINQ score was correlated with 
FEV1, and percent predicted (Wakabayashi et al., 2019). Studies have found that women require 
more education about self-management (Martinez et al., 2012; Wakabayashi et al., 2019).  This 
suggest that for female COPD patients, more exacerbations and emergency visits may occur due 
to a lack of education and that action plans might not be executed correctly (Wakabayashi et al., 
  
 18 
2019).  Wakabayashi et al. (2019) findings demonstrate why it is important to routinely assess 
cognitive function of patients at appointments. It is necessary to ensure the capacity of the patient 
to utilize information given about disease, follow up, and requirements for self-management. 
Strengths and Weaknesses Associated with Review Findings 
      The strength of the research is yet to be fully understood.  Utilization of measurement 
tools and devices to gauge disease progression and dyspnea over time is a big first step. The 
main weakness is the inability to draw any concrete conclusion on how to treat women with 
COPD in regard to symptom management and/or exacerbations of the disease process.  This is 
primarily due to a lack of studies to draw evidence from in which we should base our practice 
decisions. Repeated studies to confirm results and research involving gender specific studies will 
strengthen findings that then in turn can be used in the practice setting in the future. 
Recommendations for Clinical Practice 
      The PCP should work in collaboration with a pulmonologist to manage female patients 
with COPD. Reviewing medications, controlling various comorbidities, providing vaccinations, 
and smoking cessation education and treatment if needed are the hallmarks of the PCP’s role 
with this patient. The PCP should always review the level of dyspnea patients with COPD are 
experiencing along with their ability to manage tasks of daily living. Even with this single focus, 
the PCP may be able to assist this patient in avoiding AE-COPD. 
Recommendations for Research 
      There is a need for repeat studies involving medications available for managing patients 
with COPD. This needed research should consider gender as a way to tailor medications and 
treatments to best serve the female population. Perhaps interventional research, such as ways to 
better communicate treatment options with female patients who are experiencing COPD/COPD 
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exacerbations, will increase knowledge surrounding disease process and ultimately improve 
outcomes and reduce exacerbations. 
Recommendations for Education 
     PCPs should remain current regarding best practice related to females with COPD. 
Understanding how comorbidities affect the patient may assist in primary care appointments and 
help patient reduce AE-COPD. Patients need to know what to monitor in relation to COPD, 
proper administration of prescribed medications and treatments, how to treat symptoms of 
disease at home, when to call the PCP for assistance, and when they need to seek emergency 
care. These topics are a few key points to assist in successful disease management at home. 
Women require additional education to be successful with self-management (Martinez et al., 
2012; Wakabayashi et al., 2019). 
Recommendation for Policy 
      There should be further efforts to establish health policy once it is known and better 
understood how the role of gender impacts treatment of COPD. This review did not produce any 
QI measures. This is something that could be researched in a future review or study. Health 
policy should focus on issues surrounding readmission after exacerbations and reducing 
exacerbations overall. 
Conclusion 
      This systematic literature review was able to discern several differences between genders 
in relationship to COPD. Unfortunately, the initial PICO question was not able to be answered 
by the research findings contained within this systematic review, however it was a productive 
start for this subject and additional research should be forthcoming. There is emerging evidence 
that COPD in women is increasing and will be a burden to the healthcare system going forward.  
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Women are more susceptible to developing COPD possibly due to the anatomy of their smaller 
airways or lungs being fully developed at the time they start smoking (usually around 15 years of 
age). Regardless of the reason, women require less exposure to cigarette smoke than men to 
develop COPD. Currently there is a lack of research on pharmacological and non-
pharmacological treatment specifically for women. Due to this omission, the initial question 
asked in this systematic review cannot be answered but strongly advocates for a need for 
additional research. Women with COPD need more education about this disease to aid with their 
plan of care, the ability to self-manage, and avoid exacerbations. PCPs need to help manage 
comorbid conditions effectively as poor control of these conditions can lead to increased COPD 
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capacity and number of 
exacerbations reported 
in the year before the 
study. The distribution 
of these variables 
within each GOLD 
stage was wide. Even in 
subjects with severe 
airflow obstruction, a 
substantial proportion 





The clinical manifestations of COPD are 
highly variable, and the degree of airflow 
limitation does not capture the 
heterogeneity of the disease. 
 
Bade, B. C., DeRycke, E. 
C., Ramsey, C., Skanderson, 
M., Crothers, K., & al., e. 
(2019, June). Sex 
differences in veterans 
admitted to the hospital for 
chronic obstructive 
pulmonary disease. Annals 
of the American Thoracic 
























NA Before hospitalization, 
women were less likely 
to have pulmonary 
function testing (76% 
vs. 78%; P = 0.01) or 
be treated with 
antimuscarinic (43% vs. 
48%) or combined 
long-acting 
bronchodilator/inhaled 
This study suggests differences between 
women and men hospitalized for COPD 
regarding presentation, evaluation, and 
management. Readmission is strongly 
influenced by comorbidities, suggesting 
individualized and comprehensive case 
management may reduce readmission risk 
for women and men with COPD. 
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 exacerbatio








corticosteroid (61% vs. 
64%) inhalers. Women 
were more likely to 
receive nicotine-
replacement therapy 
(all P < 0.01). Women 
had shorter length of 
stay (median days, 2 vs. 
3; P = 0.04) and lower 
30-day readmission rate 
(20% vs. 22%; P = 
0.01). In adjusted 




diagnosis of drug or 
alcohol use were 
associated with 
readmission; there was 
no association with sex 
and readmission risk. 
 
Breyer, M.-K., Rutten, E. P., 
Vernooy, J. H., Spruit, M. 
A., Dentener, M. A., & al., 
e. (2011, July). Gender 
differences in the adipose 
secretome system in chonic 
obstructive pulmonary 
disease (COPD): a pivotal 


























for BMI with 
COPD 
subjects 
NA The COPD group was 
characterized by 
increased levels of 
CRP, IL-6, and Leptin.  
Plasma adiponectin and 
resistin concentrations 
were not different 
between the groups. 
In men with clinically stable COPD, 
leptin adiponectin and resistin appear to 
be physiologically regulated while in 
women leptin metabolism is altered.  
Leptin secretion is increased in COPD 
women when compared to healthy 
women and compare to COPD men, and 
to a greater extent in                                                                             
overweight women with COPD. 
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with 
COPD. 
Celli, B., Vestbo, J., 
Jenkins, C. R., Jones, P. W., 
Ferguson, G. T., & al., e. 
(2011, February 1). Sex 
differences in mortality and 
clinical expressions of 
patients with chronic 
obstructive pulmonary 
disease. American Journal 
of Respiratory and Critical 
































500 μg, twice 




At baseline, women 
were younger (63 vs. 66 
yr.), had higher 
FEV1 (47% vs. 44% 
predicted), and worse 
St. George's 
Respiratory 
Questionnaire (51.3 vs. 
48.7) and Medical 
Research Council score. 
During the study, 707 
(15.3%) men and 168 
(11.3%) women died. 
After adjusting for 
differences in baseline 
factors, the risk of 
dying was 16% higher 
in men than in women; 
however, this was not 
statistically significant 
(hazard ratio 1.16 [95% 
CI, 0.98–1.39]). Causes 
of death were similar in 
women and men. 
Exacerbation rate was 
25% higher in women 
than in men. 
 
Women enrolled in TORCH had a lower 
mortality rate than men but similar causes 
of death. The risk of dying was similar in 
women and men after adjusting for 
important baseline variables. Women 
reported more exacerbations, and worse 
dyspnea and health status scores than 
men. 
 
Criner, G. J., Martinez, F. J., 
Aaron, S., Agusti, A., 
Anzueto, A., & al., e. (2019, 
January). Current 
controversies in chonic 
obstructive disease. A report 
from the global initiative for 
chronic obstructive lung 
disease scientific 









NA I NA NA Women do vary from 
men for COPD risk for 
development when 
exposed to or partaking 
in smoking.  Women 
are more susceptible. 
More research is needed to decipher best 
treatment options for women. 
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de Torres, J. P., Casanove, 
C., Pinto-Plata, V., Varo, 
N., P, R., & al., e. (2011). 
Gender differences in 
plasma biomarker levels in a 
cohort of COPD patients: a 


































NA The plasma biomarkers 
level explored were 
similar in men and 
women without COPD. 
In contrast, in patients 
with COPD the median 
value in pg/mL of IL-6 
(6.26 vs 8.0, p = 0.03), 
IL-16 (390 vs 321, 
p = 0.009) and VEGF 
(50 vs 87, p = 0.02) 
differed between 
women and men. 
Adjusted for smoking 
history, gender was 
independently 
associated with IL-16, 
PARC and VEGF 
levels. There were also 
gender differences in 
the associations 
between IL-6, IL-16 
and VEGF and 
physiologic variables 
that predict outcomes. 
 
In stable COPD patients with similar 
airflow obstruction, there are gender 
differences in plasma biomarker levels 
and in the association between biomarker 
levels and important clinical or 
physiological variables. Further studies 
should confirm our findings. 
 
Ford, E. S., Mannino, D. 
M., Wheaton, A. G., 
Presley-Cantrell, L., Liu, Y., 
& al., e. (2014, April). 


















1426 III 6 national 
surveys 
N/A Medications changed 
markedly from 1999-
200 to 2009-2010. 
Many adults with 




Increased need for additional research to 
discover barriers to patients filling and 
using prescription medications. 
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Fuhrman, C., Roche, N., 
Vergnenegre, A., Zureik, 
M., Chouaid, C., & al., e. 
(2011, April). Hospital 
admissions related to acute 
exacerbations of chronic 
obstructive pulmonary 
disease. Respiratory 






































































NA In 2007, among adults 
aged 25 years or more, 
the crude AE-COPD-
related admission rates 
were 23/10000 in men 
and 10/10000 in women 
using the narrow 
definition. Using the 
broad definition, these 
rates were respectively 
38 and 16/10000. With 
the narrow definition, 
the annual number of 
AE-COPD-related 
admissions increased 
by 38% between 1998 
and 2007, while in-
hospital lethality decrea
sed from 7.6% to 6.0%. 
The proportion of male 
patients decreased from 
72% to 68%. Similar 
trends were found using 




increased by 4.4% per 
year in women and by 
1.6% per year in men 
with the narrow 
definition, and by 
respectively 3.8% and 
1.2% with the broad 
definition. A strong 
seasonal pattern of 
admissions for AE-
COPD was found, 
matching that of 
general practitioners 
Hospitalization rates for AE-COPD have 
increased in France in recent years, 
especially among women. By contrast, 
AE-COPD-related in-hospital lethality 
has decreased. 
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Kaminska, B., Rubinsztajn, 
R., Brajer-Luftmann, B., & 
Kasacka, M. (2019). COPD 
course and comorbidities: 
are there gender 
differences? Advances in 
Experimental Medicine and 
Biology, 43-51. 
 

































65.5 ± 8.8 







NA Women smoked less in 
comparison to men 
(30.4 vs. 41.9 pack-
years, p < 0.05), 
showed more 
exacerbations (2.5 vs. 
1.7, p = 0.01), higher 
forced expiratory 





but they had the same 
intensity of dyspnea. 
Women showed fewer 
comorbidities, on 
average, per patient (5.4 
vs. 6.4, p = 0.002), but 
had a higher prevalence 
of at least seven 
comorbidities per 
patient (48.7% of 
women vs. 33.0% of 
men, p < 0.05). Women 
also had a significantly 
worse prognosis (4.6 
vs. 3.1 BODE score, p 
< 0.05) that correlated 
with the number of 
comorbidities (r = 0.33, 
p < 0.01). In 
conclusion, this study 
strongly supports the 
existence of different 
gender phenotypes in 
COPD, especially 
The gender difference may indicate a 
need for a targeted assessment and 










Kohler, M., Sandberg, A., 
Kjellqvist, S., Thomas, A., 
Karimi, R., & al., e. (2013, 
March). Gender differences 
in the bronchoalveolar 
lavage cell proteome of 
patients with chronic 
obstructive pulmonary 
disease. Journal of Allergy 



















































NA Significant gender 
differences were 
unveiled, with 
numerous alterations in 
the bronchoalveolar 
lavage cell proteome 
occurring in female but 
not male patients with 
COPD. Specifically, a 
subset of 19 proteins 
provided classification 
of female healthy 
smokers from female 
patients with COPD 
with 78% predictive 
power. Subsequent 
pathway analyses 
linked the observed 
alterations to 
downregulation of the 
lysosomal pathway 
and upregulation of 
the oxidative 
phosphorylation pathwa
y, possibly linking 
dysregulation of 





This investigation makes an important 
contribution to the elucidation of putative 
molecular mechanisms underlying 
gender-based differences in 
the pathophysiology of COPD, linking 
alterations of specific molecular pathways 
to previously observed gender differences 
in clinical COPD phenotypes. 
Furthermore, these results stress the 
importance of the gender-specific search 





Martinez, C., Raparla, S., 
Plauschinat, C., Giardino, 
N. D., Rogers, B., 
Beresford, J., . . . Han, M. 
Mo Using 











NA Data on 295 female and 
273 male participants 
were analyzed. With 
similar frequencies, 
Significant gender-related differences in 
the perception of COPD healthcare 
delivery exist, revealing an opportunity to 
better understand what influences these 
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(2012). Gender differences 
in symptoms and care 
delivery for chronic 
obstructive pulmonary 
disease. Journal of Women's 

























































women and men 
reported dyspnea and 
rated their health as 
poor/very poor. 
Although more women 
than men reported 
annual household 
income <$30,000, no 
significant gender 
differences in frequency 
of health insurance, 
physician visits, or ever 
having had spirometry 
were detected. In 
adjusted models (1) 
women were more 
likely to report COPD 
diagnostic delay (odds 
ratio [OR] 1.66, 95% 
confidence interval [CI] 
1.13-2.45, p=0.01), 
although anxiety (OR 
1.83, 95% CI 1.10-
3.06, p=0.02) and 
history of exacerbations 
(OR 1.60, 95% CI 1.08-
2.37, p=0.01) were also 
significant predictors, 
(2) female gender was 
associated with 
difficulty reaching one's 
physician (OR 2.54, 
95% CI 1.33-
4.86, p=0.004), as was 
prior history of 
exacerbations (OR 2.25, 
95% CI 1.21-
4.20, p=0.01), and (3) 
female gender (OR 
2.15, 95% CI 1.10-
attitudes and to improve care for both 
men and women. 
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4.21, p=0.02) was the 
only significant 
predictor for finding 




Torres, S. H., Montes de 
Oca, M., Loeb, E., Mata, A., 
& Hernandez, N. (2011). 
Gender and skeletal muscle 
characteristics in subject 








































(61 ± 9 
years) and 
30 male 












(58 ± 8 
years), and 
9 men 
































e (LDH) were 
determined. 
 
NA Pulmonary function, 
health status and 
6MWD were similar in 
male and female COPD 
patients. Fiber type 
distribution was similar 
between women 
(I = 42 ± 9%, 
IIA = 39 ± 13%, 
IIX = 19 ± 7%) and 
men (I = 39 ± 13%, 
IIA = 38 ± 9%, 
IIX = 29 ± 10%) with 
COPD, as well as CSA, 
capillarity and enzymes 
(CS 8.59 ± 1.6 
vs.9.74 ± 2.6, HAD 
9.03 ± 1.9 vs. 
9.84 ± 2.5, LDH 124 ± 
48 vs. 
151 ± 68 μmol min−1 g−
1). In normal subjects a 
decrease in type IIX 
fibers CSA was found 
in women compared 
with men (3703 ± 1478 
vs. 5426 ± 1386 μm2, 
respectively). 
 
Female and male with COPD have 
similar skeletal muscle characteristics; it 
is possible that the disease blurs the 
gender differences. On the other hand, 
there seems to be fewer differences in 
muscle characteristics between older men 
and women, perhaps due to lower 
male testosterone levels and physical 
inactivity. 
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Vestbo, J., Agusti, A., 
Wouters, E., Bakke, P., 
Calverley, P., Celli, B., . . . 
Tal-Singer, R. (2014, May). 
Should we view chronic 
obstructive pulmory disease 
differently after ECLIPSE? 
A clinicical perspective 
from the study team. 
American Journal of 














































NA A striking heterogeneity 
among patients with 
COPD, with poor 
correlations between 
FEV1, symptoms, 
quality of life, 
functional outcomes, 
and biomarkers. 
Presence of systemic 
inflammation was 
found in only a limited 
proportion of patients, 
and did not relate to 
baseline characteristics 
or disease progression, 
but added prognostic 
value for predicting 
mortality. 
Exacerbations tracked 
over time and added to 
the concept of the 
"frequent exacerbator 
phenotype." Disease 
course was very 
variable, with close to a 
third of patients not 
progressing at all. Risk 
factors for 3-year 
change in both FEV1 
and lung density were 
assessed. For FEV1 
decline, continued 
smoking and presence 
of emphysema were the 
strongest predictors of 
progression; club cell 
protein was found to be 
a potential biomarker 
for disease activity. For 
progression of 
By following a large, well characterized 
cohort of patients with COPD over 3 
years, we have a clearer picture of a 
heterogeneous disease with clinically 
important subtypes ("phenotypes") and a 
variable and not inherently progressive 
course. 
 








Wakabayashi , R., Motegi, 
T., & Kida, K. (2019, 
January). Gender 
differences in chronic 
obstructive pulmonary 
disease using the lung 
information needs 






















































NA  Females displayed 
significantly higher 
information needs for 
total LINQ score 
(p < .001), avoidance of 
exacerbation (p < .03), 
and nutrition (p < .006). 
Significant correlations 
were seen between total 
LINQ score and gender 
(p = .001), forced 
expiratory volume in 1 




for male patients. In 
females, modified 
Medical Research 
Council dyspnea scale 
was correlated with the 
total LINQ score 
(p = .04). 
 
Behavioral differences in gender might 
have an effect on the long-term 
management of chronic diseases such as 
COPD. 
 










, and LINQ.  
Wang, L., Tao, Y.-X., 
Dong, X.-Y., Zhang, Q., 
Zheng, H., Zheng, Y.-S., . . . 




associated with disease 
severity among patients 
with chronic obstructive 
pulmonary disease. 
International Journal of 































































In multiple regression 
analysis, physical 
activity, body mass 
index, and gender were 
negatively related to 
DOSE index. 
 
The study highlighted the importance of 
physical activity, nutritional status, and 
gender difference in managing disease 
severity in COPD. Professional nurses 
should develop individualized 
intervention programs and specifically 
increase physical activity for men and 




Wedzicha, J. A., Singh, D., 
Tsiligianni, I., Jenkins, C., 
Fucile, S., Fogel, R., . . . 
Kostikas, K. (2019, January 



























genders, with women 
being younger, having 
better lung function and 
more often 
experiencing ≥2 
Although there were gender differences in 
baseline characteristics, IND/GLY 
demonstrated similar trends for 
exacerbation prevention and lung 
function improvement in men and women 
with moderate-to-very-severe COPD and 
a history of exacerbations compared with 
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salmeterol/fluticasone in 
exacerabting COPD patients 
by gender: a post-hoc 












COPD and a 
history of 
exacerbations






























exacerbations in the 
previous year. 
Compared with SFC, 
IND/GLY treatment 
was associated with 
reductions in the 
annualized rates of 
moderate/severe 
exacerbations (rate ratio 
[95% CI]: 0.81 [0.73-
0.91], 0.89 [0.74-1.07] 




exacerbation was also 
delayed (hazard ratio 
[95% CI]: 0.79 [0.70-
0.89] and 0.76 [0.63-
0.91] in men and 
women, respectively). 




Improvements in lung 
function, health status 
and rescue medication 
use with IND/GLY vs 
SFC were comparable 
between men and 
women. The smaller 
sample size for women 
may account for some 
observed discrepancies 
in treatment responses. 
 
SFC. Small differences in the effects seen 
between genders may be attributed to the 
different sizes of the two groups and need 
to be further evaluated in randomized 
trials that are appropriately powered for 
gender analysis. 
 
 
